ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0505

Transdermal Glomerular Filtration Rate Measurement in Conscious Pigs Using the Novel Fluorescent Tracer Agent Relmapirazin

Session Information

Category: Bioengineering

  • 300 Bioengineering

Authors

  • Neudecker, Sabine, MediBeacon GmbH, Mannheim, Germany
  • Schock-Kusch, Daniel, MediBeacon GmbH, Mannheim, Germany
  • Friedemann, Jochen, MediBeacon GmbH, Mannheim, Germany
  • Jostock, Marlene, mfd Diagnostics, Wendelsheim, Germany
  • Shulhevich, Yury, MediBeacon GmbH, Mannheim, Germany
  • Stsepankou, Dzmitry, MediBeacon GmbH, Mannheim, Germany
  • Ross-Jones, Jesse, MediBeacon GmbH, Mannheim, Germany
  • Johnson, James R., MediBeacon Inc., St. Louis, Missouri, United States
  • Rogers, Thomas E., MediBeacon Inc., St. Louis, Missouri, United States
  • Riley, Ivan Rochelle, MediBeacon Inc., St. Louis, Missouri, United States
  • Shieh, Jeng-Jong, MediBeacon Inc., St. Louis, Missouri, United States
  • Harr, Jim Michael, MediBeacon Inc., St. Louis, Missouri, United States
  • Dorshow, Richard B., MediBeacon Inc., St. Louis, Missouri, United States
Background

Transdermal measurement of glomerular filtration rate (tGFR) using a miniaturized fluorescence detector (“TGFR Mini Monitors”) in combination with a fluorescent exogenous GFR tracer agent is a common technique to measure kidney function in the preclinical setting, most commonly employed with rodents. However, larger animals are used in translational research on the way to human applications. The employ of an exogenous tracer agent in the preclinical setting which will also be amenable for seamless transition to human use would enhance the applicability of the preclinical data to clinical data.

Methods

The renal function of three healthy pigs (35-40 kg) was measured for 3 consecutive days. The novel fluorescent exogenous tracer agent Lumitrace™ (relmapirazin) was used in combination with two TGFR Mini Monitors per animal (MediBeacon, Germany). Excretion kinetics were measured transdermally, as well as in plasma, over the course of 4 hours. After attachment of the devices on the animal’s skin, relmapirazin was administered intravenously. Seventeen blood samples were collected to measure plasma pharmacokinetics.

Results

The slopes of the single-exponential decay of the plasma kinetics and the transdermal kinetics of relmapirazin are in agreement (Slope 0.97; R2=0.57). No statistical differences were detected using a paired t-test.

Conclusion

The collected data supports the suitability of the TGFR Mini Monitor to measure relmapirazin excretion kinetics in pigs, thus providing an important tool for translational research of GFR in larger animals.

Transcutaneous vs. Plasma renal decay time constant
Blue circles indicate the reciprocal RDTC derived from the transcutaneous and plasma measurement. The red line indicates the linear regression forced through the origin.